Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

CHEMCELL

Financiado

Chemical Engineering of Natural Killer Cells for Cancer Immunotherapy

Our immune system evolved to protect our bodies from different invaders and to fight against infections and diseases. Immune cells use sophisticated ways to detect and destroy abnormal cells, while sparing our own cells. Unluckily... ver más

29/02/2024

UOCHB AVCR

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V.V.... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-29

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UOCHB AVCR

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2017-6578-1 Plataformas automáticas de producción de células CAR T para... 136K€ Cerrado

CARLY Development and characterization of a novel CAR T-cell thera... 226K€ Cerrado

PRE2020-093534 CELULAS T GENETICAMENTE MODIFICADAS PARA EXPRESAR RECEPTORES... 99K€ Cerrado

I-CREATE Fighting cancer with next generation oncolytic immunotherapy... 5M€ Cerrado

PID2021-128283OA-I00 CELULAS CAR-T FRENTE A ANTIGENOS DEL MICROAMBIENTE TUMORAL C... 157K€ Cerrado

RYC2018-024442-I Chimeric Antigen Receptor (CAR)-modified T cells for the tre... 309K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2022-08-09
Fecha Fin: 2024-02-29

Líder del proyecto

USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V.V.... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Our immune system evolved to protect our bodies from different invaders and to fight against infections and diseases. Immune cells use sophisticated ways to detect and destroy abnormal cells, while sparing our own cells. Unluckily, cancer cells often develop sneaky tricks enabling them to evade this protecting machinery and to survive and proliferate. Immunotherapy, an emerging concept of treatment, aims to employ the power of immune system to fight cancer by boosting or reeducation of immune cells. One of the approaches, the adoptive cell transfer therapy, especially in the form of chimeric antigen receptor (CAR) cells, has shown an unprecedented success in the treatment of certain types of cancer. CAR cells are genetically modified immune cells engineered to recognize and kill cells with specific cancer antigen. Unfortunately, production of genetically modified CARs is problematic, inefficient, time consuming and therefore, associated with high costs. New approaches enabling production of modified immune cells more effectively, faster and cheaper could therefore change the way the therapy is used. Within this proposal, we will explore the potential of an innovative approach for production of chemically engineered immune cells and their application in immunotherapy. In particular, we will employ our technology based on combination of metabolic engineering and subsequent biocompatible chemical labeling to produce an antibody modified natural killer (NK) cells that we will investigate in cancer killing experiments. We will perform a side-by-side comparison of our technology with the ‘traditional’ CAR-NK cells both, in vitro and in vivo, to evaluate the pros and cons of both approaches. Finally, in collaboration with our Tech Transfer Office, we will present the technology to potential stakeholders to bring it to the next step in the form of patent licensing or eventually, develop the technology further within spin-out company.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores